| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $350,000 | 2 | 100 |
Sells | $0 | 0 | 0 |
| KLEMP WALTER V | CEO and President | 1 | $250,000 | 0 | $0 | $250,000 |
| Foster Jonathan P. | Chief Financial Officer | 1 | $100,000 | 0 | $0 | $100,000 |
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Over the last 12 months, insiders at Moleculin Biotech, Inc. have bought $350,000 and sold $0 worth of Moleculin Biotech, Inc. stock.
On average, over the past 5 years, insiders at Moleculin Biotech, Inc. have bought $233,789 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: KLEMP WALTER V (CEO and President) — $250,000. Foster Jonathan P. (Chief Financial Officer) — $100,000.
The last purchase of 675,675 shares for transaction amount of $250,000 was made by KLEMP WALTER V (CEO and President) on 2025‑06‑23.
| 2025-06-23 | KLEMP WALTER V | CEO and President | 675,675 6.4607% | $0.37 | $250,000 | +50.37% | ||
| 2025-06-23 | Foster Jonathan P. | Chief Financial Officer | 270,270 2.5843% | $0.37 | $100,000 | +50.37% | ||
| 2023-12-26 | KLEMP WALTER V | CEO and President | 188,404 0.6709% | $0.69 | $129,999 | -59.21% | ||
| 2023-12-26 | Foster Jonathan P. | Chief Financial Officer | 28,986 0.1032% | $0.69 | $20,000 | -59.21% | ||
| 2023-12-26 | George Robert E. | director | 14,493 0.0516% | $0.69 | $10,000 | -59.21% | ||
| 2022-11-25 | KLEMP WALTER V | CEO and President | 45,000 0.1562% | $1.28 | $57,632 | -49.25% | ||
| 2022-11-21 | KLEMP WALTER V | CEO and President | 22,500 0.0729% | $1.15 | $25,866 | -46.83% | ||
| 2022-11-17 | KLEMP WALTER V | CEO and President | 24,742 0.0849% | $1.02 | $25,257 | -36.28% | ||
| 2022-11-16 | KLEMP WALTER V | CEO and President | 85,213 0.2832% | $0.97 | $82,614 | -34.97% | ||
| 2017-08-16 | Sale | Priebe Waldemar | 10 percent owner | 200,000 0.6259% | $1.70 | $340,600 | -30.57% | |
| 2017-08-16 | Sale | KLEMP WALTER V | Chief Executive Officer | 200,000 0.6259% | $1.70 | $340,600 | -30.57% | |
| 2017-05-11 | KLEMP WALTER V | Chief Executive Officer | 24,000 0.133% | $0.81 | $19,440 | +128.51% | ||
| 2017-05-05 | Northcut Jacqueline | director | 2,000 0.0057% | $0.41 | $820 | +133.75% | ||
| 2017-04-28 | George Robert E. | director | 2,000 0.0058% | $0.47 | $938 | +105.49% | ||
| 2017-04-25 | Foster Jonathan P. | Exec. Vice President & CFO | 20,000 0.1113% | $0.86 | $17,298 | +114.94% |
| KLEMP WALTER V | CEO and President | 743607 61.4998% | $3.23M | 7 | 1 | <0.0001% |
| Foster Jonathan P. | Chief Financial Officer | 287587 23.7848% | $1.25M | 3 | 0 | +27.87% |
| Priebe Waldemar | 10 percent owner | 2781573 230.0494% | $12.07M | 0 | 1 | |
| George Robert E. | director | 14660 1.2125% | $63,624.40 | 2 | 0 | +23.14% |
| Northcut Jacqueline | director | 1000 0.0827% | $4,340.00 | 1 | 0 | +133.75% |
$13,664,154 | 40 | -70.35% | $5.12M | |
$1,029,337 | 36 | -28.38% | $5.9M | |
$1,138,733 | 28 | -4.94% | $3.28M | |
$29,635,355 | 27 | 9.05% | $4.26M | |
$63,749,694 | 24 | -12.24% | $5.74M | |
$337,688 | 19 | -33.30% | $4.25M | |
$949,171 | 17 | -8.46% | $6.61M | |
$742,412 | 14 | -50.36% | $5.28M | |
Moleculin Biotech, Inc. (MBRX) | $389,864 | 11 | 12.52% | $5.25M |
$684,058 | 11 | -57.59% | $4.94M | |
$120,379 | 10 | -24.48% | $7.65M | |
$8,971,546 | 8 | 6.18% | $4.17M | |
$211,895 | 8 | -39.70% | $6.69M | |
$159,974 | 7 | -18.60% | $6.5M | |
$192,099 | 7 | -39.17% | $5.03M | |
$76,299 | 4 | 11.60% | $4.93M | |
$1,057,000 | 3 | 5.27% | $6.38M | |
$31,190 | 2 | -14.18% | $7.27M | |
$4,423 | 2 | 3.27% | $4.8M |
| Increased Positions | 13 | +41.94% | 27,496 | +106.69% |
| Decreased Positions | 13 | -41.94% | 11,827 | -45.89% |
| New Positions | 7 | New | 8,355 | New |
| Sold Out Positions | 11 | Sold Out | 11,825 | Sold Out |
| Total Postitions | 31 | 0% | 41,441 | +60.8% |
| Vanguard Group Inc | $35.00 | 0.32% | 9,597 | +8,360 | +675.83% | 2025-09-30 |
| Geode Capital Management, Llc | $30.00 | 0.28% | 8,328 | +7,227 | +656.4% | 2025-09-30 |
| Hrt Financial Lp | $17.00 | 0.15% | 4,608 | +4,608 | New | 2025-09-30 |
| Lpl Financial Llc | $8.00 | 0.08% | 2,323 | +80 | +3.57% | 2025-09-30 |
| Ieq Capital, Llc | $5.00 | 0.05% | 1,455 | +1,455 | New | 2025-09-30 |
| Wealth Dimensions Group, Ltd. | $3.00 | 0.03% | 800 | +800 | New | 2025-09-30 |
| Rockefeller Capital Management L.P. | $2.00 | 0.02% | 580 | +580 | New | 2025-09-30 |
| Cambridge Investment Research Advisors, Inc. | $2.00 | 0.02% | 511 | 0 | 0% | 2025-09-30 |
| Goldman Sachs Group Inc | $2.00 | 0.02% | 510 | +510 | New | 2025-09-30 |
| Blackrock, Inc. | $2.00 | 0.02% | 495 | 0 | 0% | 2025-09-30 |